- Home
- ME
as 09-16-2024 4:00pm EST
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 168.9M | IPO Year: | N/A |
| Target Price: | $0.47 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.29 - $1.10 | Next Earning Date: | 11-06-2024 |
| Revenue: | $199,188,000 | Revenue Growth: | -32.67% |
| Revenue Growth (this year): | 0.05% | Revenue Growth (next year): | 17.98% |
Latest 23andMe Holding Co. News
ME Breaking Stock News: Dive into ME Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
GlobeNewswire
2 days ago
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
Reuters
3 days ago
23andMe settles data breach lawsuit for $30 million
GlobeNewswire
4 days ago
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
Reuters
5 days ago
23andMe CEO Wojcicki open to third-party takeover proposals for firm, filing shows
MT Newswires
5 days ago
23andMe Holding Investor Anne Wojcicki Open to Weighing Takeover Proposals
GlobeNewswire
13 days ago
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
MT Newswires
19 days ago
23andMe Holding's Subsidiary Offering Obesity Drugs Through Subscription-Based Weight Loss Program
Compare ME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ME 23andMe Holding Co. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.